Sagent Pharmaceuticals, Inc. announced the launch of amikacin sulfate injection, USP, an anti-infective/antibiotic, in 500 mg per 2 mL and 1 g per 4 mL preservative-free vials.

According to IMS, for the 12 months ending May 2016, the US market for amikacin approximated $8 million. As with all products in Sagent's portfolio, amikacin features Sagent's PreventIV MeasuresSM Packaging and Labeling, designed to help reduce the risk of medication errors.

Amikacin sulfate injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species and Acinetobacter (Mima-Herellea) species.

Sagent Pharmaceuticals, Inc., founded in 2006, is a leading provider of affordable pharmaceuticals to the hospital market.